Contributions
Abstract: PB1717
Type: Publication Only
Background
Previous epidemiological studies have shown that autoimmune diseases increase the risk of lymphoma development. Immune dysregulation could be the possible underlying pathogenesis. Whether autoimmune diseases deteriorate outcome of lymphoma patients, however, remains unclear.
Aims
The objective of this study is to compare the clinical outcome among lymphoma patients with and without autoimmune diseases.
Methods
From January 2008 to November 2016, we retrospectively reviewed medical records of 913 newly diagnosed lymphoma patients. From these 913 lymphoma patients, 34 (3.71%) patients were diagnosed to have autoimmune diseases before their lymphoma identification. Among these 34 patients, six patients lost their follow-up. A total of 28 lymphoma patients with pre-existing autoimmune diseases were finally analyzed. For the further comparison, 56 lymphoma patients without pre-existing autoimmune diseases who were adjusted for age and gender were considered to be the control group. Response rate, progression-free survival (PFS), and overall survival (OS) were compared between these two groups of patients.
Results
Rheumatoid arthritis was the most common autoimmune disease in lymphoma patients (11/34; 32.3%). The complete remission rate for lymphoma patients with and without autoimmune diseases were 72.0% and 83.3%, respectively (p=0.178). The PFS for patients with and without autoimmune diseases were 44.3 ± 32.1 months and 50.9 ± 28.6 months, respectively (mean ± standard deviation; p=0.334). These two groups of patients had similar OS time as well (46.4 ±31.5 months vs. 52.9 ± 28.0; mean ± standard deviation; p=0.337). Univariate analysis did not show autoimmune diseases were associated with inferior OS in lymphoma patients (crude hazard ratio: 1.32; 95% confidence interval: 0.43 - 4.07; P=0.627).
Conclusion
The results of this case-control study showed the autoimmune disease was not a poor prognostic factor for lymphoma patients.
Session topic: 20. Aggressive Non-Hodgkin lymphoma - Clinical
Keyword(s): lymphoma, Autoimmune disease
Abstract: PB1717
Type: Publication Only
Background
Previous epidemiological studies have shown that autoimmune diseases increase the risk of lymphoma development. Immune dysregulation could be the possible underlying pathogenesis. Whether autoimmune diseases deteriorate outcome of lymphoma patients, however, remains unclear.
Aims
The objective of this study is to compare the clinical outcome among lymphoma patients with and without autoimmune diseases.
Methods
From January 2008 to November 2016, we retrospectively reviewed medical records of 913 newly diagnosed lymphoma patients. From these 913 lymphoma patients, 34 (3.71%) patients were diagnosed to have autoimmune diseases before their lymphoma identification. Among these 34 patients, six patients lost their follow-up. A total of 28 lymphoma patients with pre-existing autoimmune diseases were finally analyzed. For the further comparison, 56 lymphoma patients without pre-existing autoimmune diseases who were adjusted for age and gender were considered to be the control group. Response rate, progression-free survival (PFS), and overall survival (OS) were compared between these two groups of patients.
Results
Rheumatoid arthritis was the most common autoimmune disease in lymphoma patients (11/34; 32.3%). The complete remission rate for lymphoma patients with and without autoimmune diseases were 72.0% and 83.3%, respectively (p=0.178). The PFS for patients with and without autoimmune diseases were 44.3 ± 32.1 months and 50.9 ± 28.6 months, respectively (mean ± standard deviation; p=0.334). These two groups of patients had similar OS time as well (46.4 ±31.5 months vs. 52.9 ± 28.0; mean ± standard deviation; p=0.337). Univariate analysis did not show autoimmune diseases were associated with inferior OS in lymphoma patients (crude hazard ratio: 1.32; 95% confidence interval: 0.43 - 4.07; P=0.627).
Conclusion
The results of this case-control study showed the autoimmune disease was not a poor prognostic factor for lymphoma patients.
Session topic: 20. Aggressive Non-Hodgkin lymphoma - Clinical
Keyword(s): lymphoma, Autoimmune disease